Screening of aptamers specific to colorectal cancer cells and stem cells by utilizing On-chip Cell-SELEX

65Citations
Citations of this article
81Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Colorectal cancer (CRC) is the most frequently diagnosed cancer around the world, causing about 700,000 deaths every year. It is clear now that a small fraction of CRC, named colorectal cancer stem cells (CSCs) exhibiting self-renewal and extensive proliferative activities, are hard to be eradicated. Unfortunately, highly specific biomarkers for colorectal CSC (CR-CSCs) are lacking that prohibits the development of effective therapeutic strategies. This study designed and manufactured a novel microfluidic system capable of performing a fully automated cell-based, systematic evolution of ligands by exponential enrichment (SELEX) process. Eight CR-CSC/CRC-specific aptamers were successfully selected using the microfluidic chip. Three of the aptamers showed high affinities towards their respective target cells with a dissociation constant of 27.4, 28.5 and 12.3 nM, which are comparable to that of antibodies.

Cite

CITATION STYLE

APA

Hung, L. Y., Wang, C. H., Che, Y. J., Fu, C. Y., Chang, H. Y., Wang, K., & Lee, G. B. (2015). Screening of aptamers specific to colorectal cancer cells and stem cells by utilizing On-chip Cell-SELEX. Scientific Reports, 5. https://doi.org/10.1038/srep10326

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free